Submission of Matters to a Vote of Security Holders Form 8 K

On June 27, 2024, Aligos Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). As further described in Item 5.07 of this Current Report on Form 8-K,at the Annual Meeting, the Company's stockholders approved an amendment (the "2020 Plan Amendment") to the Company's 2020 Incentive Award Plan (the "2020 Plan"). The 2020 Plan Amendment was approved by the Board of Directors (the "Board") on March 1, 2024 and became effective upon stockholder approval at the Annual Meeting.

The 2020 Plan Amendment amends the 2020 Plan (as amended, the "Amended Plan") to treat outstanding pre-fundedwarrants with an exercise price per share equal to a penny or less the same as outstanding common stock such that beginning in 2025 and ending in 2030, annual increases to the shares of common stock reserved for issuance under the 2020 Plan will equal the lesser of (i) 5% of the shares of common stock outstanding or issuable upon exercise of outstanding pre-fundedwarrants with an exercise price per share equal to a penny or less, in each case, as of the last day of the immediately preceding fiscal year or (ii) such smaller number of shares determined by the Board.

The terms and conditions of the Amended Plan are described in the section entitled "Proposal 4 - Approval of Amendment to our 2020 Incentive Award Plan" included in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 (the "Proxy Statement"). This description is incorporated by reference into Item 5.02 of this Current Report on Form 8-K.

The above and the incorporated descriptions of the Amended Plan are qualified in their entirety by reference to the 2020 Plan Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-Kand incorporated by reference herein.